Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Activity of Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

NCT06302569 is registered in ClinicalTrials.gov with Giuseppe Procopio as lead sponsor.

NCT NCT06302569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06302569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Activity of Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Lead sponsor
Giuseppe Procopio
Phase
Phase 2
Overall status
Recruiting
Start date
May 30, 2025
Completion date
May 31, 2029
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bellini carcinoma, collecting duct carcinoma, renal medullary carcinoma